10-K/A: Shuttle Pharmaceuticals Restates Financials, Cites Material Weaknesses in Internal Controls

Shuttle Pharmaceuticals Holdings, Inc. has amended its annual report to restate its financial statements for 2022 and 2023 due to accounting errors and material weaknesses in internal controls.

Summary

• Shuttle Pharmaceuticals has restated its financial statements for the years ended December 31, 2022 and 2023, and the quarterly periods included in the 2023 Form 10-K, and the quarterly report for the period ended March 31, 2024.
• The restatement was prompted by a cease-and-desist order against the company's former auditor, BF Borgers CPA PC, and a subsequent re-audit by Forvis Mazars LLP.
• The company identified material weaknesses in its internal controls over financial reporting, which contributed to the need for the restatement.
• The company's net loss for 2023 was approximately $6.6 million, with no revenues, and working capital of approximately $4.6 million as of December 31, 2023.
• The company's ability to continue as a going concern is dependent on its ability to raise additional capital.
• The company completed a 1-for-8 reverse stock split on August 13, 2024, to regain compliance with Nasdaq listing rules.
• The company has a convertible note payable outstanding at December 31, 2023, which includes covenants and certain cash payment requirements.

Sentiment

Score: 4

Explanation: The document reveals significant financial challenges, including a restatement of financials, material weaknesses in internal controls, and a need for additional capital. While there are some positive developments, such as the FDA approval for the Phase II study, the overall sentiment is negative due to the financial and operational risks.

Positives

• The company received a Safe to Proceed letter from the FDA for its Phase II study of Ropidoxuridine.
• The company has engaged a CRO to oversee the Phase II clinical trial.
• The company has completed GMP manufacture of Ropidoxuridine for use in clinical trials.
• The company has completed the formulation of Ropidoxuridine capsules for use in clinical trials.

Negatives

• The company has incurred losses since inception and had a net loss of approximately $6.6 million for the year ended December 31, 2023.
• The company has no source of product sales revenue.
• The company has identified material weaknesses in its internal controls over financial reporting.
• The company's ability to continue as a going concern is dependent on its ability to raise additional capital.
• The company's stock price has been extremely volatile.
• The company's convertible note payable includes covenants and certain cash payment requirements.

Risks

• The company's ability to continue as a going concern is dependent upon raising additional capital.
• The company's success is dependent on the successful development, regulatory approval, and commercialization of its product candidates.
• The company faces competition from other pharmaceutical and biotechnology companies.
• The company may be unable to obtain or enforce patent protection for its technologies.
• The company may be subject to third-party claims of patent infringement.
• The company relies on third-party manufacturers and suppliers.
• The company may be unable to obtain U.S. or foreign regulatory approval for its product candidates.
• The company's stock price may be volatile.
• The company's financial statements have been restated due to accounting errors and material weaknesses in internal controls.

Future Outlook

The company plans to continue its research and development efforts, advance Ropidoxuridine clinical testing, and explore new SBIR contract work. The company intends to initiate a rights offering for $4.5 million and has submitted SBIR applications for non-dilutive NIH funding for its pre-clinical project.

Management Comments

• Management intends to initiate a rights offering for $4.5 million and has submitted SBIR applications for non-dilutive NIH funding for our pre-clinical project.
• Management is committed to maintaining a strong internal control environment.

Industry Context

The company operates in the competitive pharmaceutical industry, specifically in the area of cancer therapeutics and radiation sensitizers. The company's product candidates are designed to address the limitations of current cancer therapies and improve patient outcomes. The market for radiation sensitizing agents is experiencing dynamic growth through development of new radiation technology, the introduction of new agents, growth in the number of diagnosed patients in a variety of cancers and changes in treatment patterns.

Comparison to Industry Standards

• The company's reliance on third-party manufacturers is common in the pharmaceutical industry, especially for smaller companies.
• The company's focus on developing novel radiation sensitizers is aligned with the industry trend of improving cancer treatment outcomes.
• The company's financial losses and need for additional funding are typical for clinical-stage pharmaceutical companies.
• The company's restatement of financial statements and identification of material weaknesses in internal controls is a significant concern and is not typical of well-established companies.
• The company's reverse stock split is a common strategy for companies facing delisting from major stock exchanges.
• The company's engagement of a CRO to oversee the Phase II clinical trial is a standard practice in the pharmaceutical industry.
• The company's receipt of a Safe to Proceed letter from the FDA is a positive milestone, but it is not uncommon for companies to face challenges in clinical trials.

Management Changes

Corporate Governance

Related Party Transactions

• The company had loan agreements with the spouse of an officer and an officer of the company.
• The company has a manufacturing agreement with TCG GreenChem, Inc., where one of the company's independent directors is CEO and CSO.

Stakeholder Impact

• Shareholders face the risk of dilution due to potential capital raises.
• Employees may be affected by the company's financial instability.
• Customers may be impacted by delays in product development and commercialization.
• Suppliers and creditors may face increased risk due to the company's financial challenges.

Next Steps

• The company will commence its Phase II clinical study in the second quarter of 2024.
• The company will continue to pursue additional funding through public or private equity or debt financings or other sources.
• The company will continue to implement measures to remediate the identified material weaknesses in internal controls.

Key Dates

Keywords

Ropidoxuridine, radiation sensitizer, HDAC inhibitors, glioblastoma, clinical trials, financial restatement, internal controls, reverse stock split, FDA approval, cancer therapy